Sponsored

Imugene Limited (ASX:IMU) Proceeds to Next Dose Escalation in PD1-Vaxx’s Phase 1 Trial

  • January 22, 2021 05:12 PM AEDT
  • Team Kalkine
    Team Kalkine
    admin Team Kalkine
    16956 Posts

    Team Kalkine comprises of experts who understand various markets nuances and are enthusiastic and passionate to provide best possible offerings in the form of insights and stories. The team has rich experience of working across different markets with...

Imugene Limited (ASX:IMU) Proceeds to Next Dose Escalation in PD1-Vaxx’s Phase 1 Trial

Summary

  • Imugene Limited (ASX:IMU) has received the approval from CRC to progress to second dose cohort in PD-1 Vaxx’s Phase I clinical trial.
  • The CRC has unanimously agreed on PD1-Vaxx to be safe following a review of the first low dose cohort of patient’s data.
  • Imugene is also progressing with the Phase 1 trial of PD1-Vaxx in the USA.

Marking a major breakthrough, Imugene Limited (ASX:IMU) has obtained the Cohort Review Committee’s (CRC) approval for the ongoing PD-1 Vaxx’s Phase I clinical trial. The Cohort Review Committee has validated that the Phase 1 trial of PD1-Vaxx will progress to the second dose cohort.

In mid-December 2020, Imugene completed the enrolment of the first cohort of patients with low-dose PD1-Vaxx at the Cabrini Hospital in Melbourne and Macquarie Hospital in Sydney. Three patients with non-small cell lung cancer were successfully dosed as part of the first cohort.

Related Read: Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

Medical investigators are testing three separate doses of PD1-Vaxx in patients with non-small cell lung cancer under Phase 1, multi-centre, dose-escalation study. The key objective of the trial is to ascertain an optimal biological dose as a monotherapy (mOBD) and determine safety.

The Cohort Review Committee will determine the optimal biological dose that requires successive dosing of PD1-Vaxx within cohorts of minimum three patients each.

CRC’s Approval for 2nd PD1-Vaxx Phase 1 Cohort

The Cohort Review Committee evaluated all tolerability and safety data for the first three patients dosed with the minimum dose of PD1-Vaxx (i.e., 10mcg) as monotherapy. The committee observed no serious adverse reactions & no dose-limiting toxicities (DLTs), and unanimously agreed on PD1-Vaxx to be safe.

After reviewing the first low dose cohort of patient’s data, the CRC has recommended continuing to the subsequent dose escalation due to tolerability and safety. Principal Investigator Professor Gary Richardson from the Cabrini Hospital has confirmed the same.

Imugene informed that the Cohort Review Committee has advised the Company to proceed with initiating the second PD1-Vaxx Phase 1 cohort at the mid-dose level of 50mcg.

Phase 1 Trial Underway in the USA

Besides Australia, Imugene is also progressing with the Phase 1 trial of PD1-Vaxx in the USA following the receipt of US FDA Investigational New Drug (IND) approval. The FDA IND approval is a huge milestone for the Company, which has been granted after a gold-standard scientific and regulatory review.

Must Read: Imugene (ASX:IMU) Wins FDA IND Approval to Kick Off PD1-Vaxx’s Phase 1 Trial in US

The Company also holds Independent Review Boards’ (IRBs) approval to proceed with the Phase 1 trial of PD1-Vaxx in the USA. The approval reflects that it is scientifically and ethically appropriate to progress with the PD1-Vaxx clinical trial.

Imugene has recently notified that clinicians at study sites in the USA and Australia will determine whether the administration of the Company’s PD1-Vaxx as monotherapy in lung cancer patients who have progressed on SOC (standard of care) immune checkpoint inhibitors will:

  • delay tumour progression,
  • reduce the tumour burden, or
  • prolong survival.

Imugene shares traded at $0.115 on 22 January 2021.

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK